Want to see INBX full AI Analyst Report?
Top Page
Inhibrx Biosciences Inc
(NASDAQ:INBX)
Select Model
Select Model
Rating:58Neutral
Price Target:
$126.00
▲(2.67% Upside)
Action:Reiterated
Date:09/09/26
Overall score is held back primarily by very weak financial performance (minimal/zero TTM revenue, large losses, heavy cash burn, and negative equity). Offsetting this, the stock’s technical trend and momentum are strong, and recent corporate events (BLA acceptance, encouraging Phase 2 data, and expanded financing capacity) provide notable fundamental catalysts, though valuation remains challenged due to ongoing losses and no dividend.
Positive Factors
Regulatory pathway for ozekibart
FDA acceptance of ozekibart’s BLA and the April 2027 decision date create a defined regulatory path for a potential first commercial product. If approved, the therapy could move Inhibrx from a development-stage model toward recurring product revenue and broader commercial operations.
Negative Factors
No established commercial revenue
The absence of meaningful recurring revenue leaves Inhibrx dependent on future approvals, partnerships, or financing rather than an established commercial franchise. Until a product launches successfully, revenue visibility remains low and operating performance is unlikely to be self-sustaining.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory pathway for ozekibart
FDA acceptance of ozekibart’s BLA and the April 2027 decision date create a defined regulatory path for a potential first commercial product. If approved, the therapy could move Inhibrx from a development-stage model toward recurring product revenue and broader commercial operations.
Read all positive factors
Inhibrx Biosciences Inc (INBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.68B
Dividend Yield5.23%
Average Volume (3M)256.12K
Price to Earnings (P/E)―
Beta (1Y)1.33
Revenue Growth-100.00%
EPS Growth19.23%
CountryUS
Employees110
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.88
Shares Outstanding14,717,660
10 Day Avg. Volume294,210
30 Day Avg. Volume256,116
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)153.07
Price to Sales (P/S)941.13
P/FCF Ratio-9.42
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$266.67Price Target Upside117.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-9.41
Revenue Forecast (FY)N/A
Inhibrx Biosciences Inc Business Overview & Revenue Model
Company Description
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic ca...
How the Company Makes Money
Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company and does not have a stable, product-based commercial revenue stream typical of mature pharmaceutical companies. The company’s cash inflows generally come from (1) collaboration an...
Inhibrx Biosciences Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 1.30M | 200.00K | 1.80M | 2.19M | 7.13M |
| Gross Profit | -1.68M | -1.18M | -2.08M | 609.00K | -107.99M | 4.44M |
| EBITDA | -120.45M | -125.37M | 1.70B | -206.69M | -125.82M | -76.55M |
| Net Income | -138.18M | -140.06M | 1.69B | -241.36M | -145.23M | -81.77M |
Balance Sheet | ||||||
| Total Assets | 154.22M | 146.48M | 180.77M | 307.89M | 290.88M | 150.45M |
| Cash, Cash Equivalents and Short-Term Investments | 133.34M | 124.22M | 152.60M | 277.92M | 273.87M | 131.30M |
| Total Debt | 5.34M | 107.01M | 8.05M | 210.14M | 207.10M | 72.14M |
| Total Liabilities | 207.20M | 138.49M | 47.18M | 264.39M | 232.82M | 98.07M |
| Stockholders Equity | -52.98M | 7.99M | 133.58M | 43.50M | 58.06M | 52.38M |
Cash Flow | ||||||
| Free Cash Flow | -131.87M | -129.82M | -197.01M | -197.90M | -115.99M | -81.19M |
| Operating Cash Flow | -131.89M | -129.79M | -194.41M | -193.31M | -115.30M | -80.32M |
| Investing Cash Flow | 20.00K | -28.00K | -2.60M | -4.59M | -686.00K | -809.00K |
| Financing Cash Flow | 78.67M | 101.45M | 71.68M | 201.96M | 258.55M | 83.77M |
Inhibrx Biosciences Inc Technical Analysis
Positive
122.72
Price Trends
97.93
Positive
102.12
Positive
89.30
Positive
Market Momentum
7.19
Positive
54.83
Neutral
56.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBX, the sentiment is Positive. The current price of 122.72 is above the 20-day moving average (MA) of 111.10, above the 50-day MA of 97.93, and above the 200-day MA of 89.30, indicating a bullish trend. The MACD of 7.19 indicates Positive momentum. The RSI at 54.83 is Neutral, neither overbought nor oversold. The STOCH value of 56.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INBX.
Inhibrx Biosciences Inc Risk Analysis
Inhibrx Biosciences Inc disclosed 89 risk factors in its most recent earnings report. Inhibrx Biosciences Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inhibrx Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.68B | -12.71 | 1893.60% | 5.23% | -100.00% | 19.23% | |
58 Neutral | $2.01B | -13.44 | -72.07% | ― | -69.78% | -106.07% | |
57 Neutral | $1.88B | -11.49 | -28.66% | ― | -28.56% | 10.25% | |
56 Neutral | $3.71B | -20.46 | -17.49% | ― | 101.28% | 2.49% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
48 Neutral | $1.82B | -191.18 | -2.35% | ― | 20.19% | ― | |
45 Neutral | $1.41B | -4.92 | -47.04% | ― | -65.40% | -164.71% |
* General Sector Average
INBX
Inhibrx Biosciences Inc
112.86
85.21
308.17%
XNCR
Xencor
24.94
16.58
198.33%
ZYME
Zymeworks
27.15
11.96
78.74%
IMTX
Immatics
9.11
3.30
56.80%
ABCL
AbCellera Biologics
11.05
6.77
158.18%
IMCR
Immunocore Holdings
34.47
-1.94
-5.32%
Inhibrx Biosciences Inc Corporate Events
Business Operations and StrategyProduct-Related Announcements
Inhibrx Biosciences reports strong Phase 2 INBRX-106 data
Positive
Sep 8, 2026
On September 8, 2026, Inhibrx Biosciences reported primary endpoint data from the randomized Phase 2 HexAgon trial of INBRX-106 plus pembrolizumab versus pembrolizumab alone in first-line PD-L1–positive metastatic or unresectable recurrent h...
Business Operations and StrategyPrivate Placements and Financing
Inhibrx Biosciences Expands Credit Facility to $500 Million
Positive
Jul 17, 2026
On July 15, 2026, Inhibrx Biosciences Inc. amended its Loan and Security Agreement with Oxford Finance, expanding its credit facility to as much as $500 million and adding a new $325 million tranche. The company received an immediate $100 million ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy
Positive
Jun 15, 2026
On June 15, 2026, Inhibrx Biosciences Inc. announced that the U.S. Food and Drug Administration accepted for filing its Biologics License Application for ozekibart (INBRX-109) to treat patients with unresectable or metastatic conventional chondros...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.